새우 질병 진단 시장 : 기술별, 진단 방법별, 질병 유형별, 용도별, 최종 사용자별 시장 예측(2026-2032년)

The Shrimp Disease Diagnostics Market is projected to grow by USD 894.80 million at a CAGR of 8.43% by 2032.

Shrimp Disease Diagnostics Market Introduction

Shrimp disease diagnostics is becoming a strategic control point for sustainable aquaculture, seafood trade, and biosecurity. Viral, bacterial, fungal, and parasitic conditions such as white spot syndrome virus (WSSV), acute hepatopancreatic necrosis disease (AHPND), Enterocytozoon hepatopenaei (EHP), infectious hypodermal and hematopoietic necrosis virus (IHHNV), Taura syndrome virus (TSV), and infectious myonecrosis virus (IMNV) continue to shape farm productivity, survival rates, and market access.

The market is moving from symptom-based farm decisions toward evidence-led testing using PCR, qPCR, loop-mediated isothermal amplification, immunoassays, histopathology, sequencing, and digital surveillance. Demand is strongest where shrimp farming, hatchery management, broodstock screening, feed optimization, biosecurity protocols, and export certification intersect, making accurate shrimp pathogen detection essential for risk reduction, traceable production, and premium supply assurance.

Transformative Shifts in Shrimp Diagnostics

The shrimp disease diagnostics landscape is shifting from reactive outbreak confirmation to preventive health intelligence. Farms, hatcheries, processors, and veterinary laboratories are increasingly adopting routine surveillance to detect pathogens before clinical signs appear, particularly for high-impact diseases recognized by the World Organisation for Animal Health and national aquatic animal health authorities.

A second shift is the decentralization of testing. Portable PCR, LAMP-based assays, rapid sample preparation, cloud-connected reporting, and farm-level sampling protocols are shortening decision cycles. This transformation supports faster pond segregation, seed selection, water-quality intervention, movement controls, and harvest timing, while strengthening traceability for importers, retailers, and food safety regulators.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is compounding the value of shrimp disease diagnostics by connecting laboratory results with environmental, operational, and production data. Machine learning models can analyze patterns in water temperature, salinity, dissolved oxygen, stocking density, feed conversion, mortality, weather variability, and pathogen load to improve early-warning systems.

AI also improves diagnostic workflow efficiency through image analysis for histopathology, automated interpretation of amplification curves, anomaly detection in surveillance datasets, and risk scoring across farms and production zones. The cumulative impact is not the replacement of validated assays, but the creation of decision-support systems that help producers prioritize sampling, predict outbreaks, allocate biosecurity resources, and respond with greater precision.

Key Regional Insights: Asia-Pacific, North America, Latin America, Europe, Middle East, and Africa

Asia-Pacific remains the center of gravity for shrimp production and shrimp disease diagnostics because China, India, Vietnam, Indonesia, Thailand, Bangladesh, and other regional producers support large aquaculture footprints and export-oriented supply chains. Regional priorities include hatchery biosecurity, post-larvae screening, WSSV control, AHPND monitoring, EHP management, broodstock certification, and farm-level surveillance, with increasing use of qPCR, PCR panels, and molecular pathogen detection to support disease prevention and movement control.

North America and Europe are comparatively smaller shrimp farming regions but influential diagnostic, regulatory, and seafood-import markets. The United States, Canada, the European Union, and the United Kingdom emphasize food safety, pathogen documentation, laboratory accreditation, traceability, and import compliance. Latin America, led by Ecuador, Mexico, and Brazil, is strengthening farm surveillance, hatchery quality programs, and export assurance as shrimp trade expands. The Middle East is advancing controlled-environment aquaculture, food security strategies, and aquatic animal health capacity, while Africa is building biosecure aquaculture zones, diagnostic access, and climate-resilient disease monitoring to support emerging shrimp farming systems.

Key Group Insights: ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN is a critical diagnostic demand cluster because several member economies are major shrimp producers and exporters, with disease control priorities centered on hatchery certification, farm biosecurity, post-larvae quality, and rapid response to transboundary aquatic animal diseases. The region's focus is moving toward harmonized testing practices, molecular surveillance, and stronger reporting systems to support seafood trade and improve confidence in shrimp supply chains.

The European Union and G7 influence global diagnostic standards through import controls, laboratory quality systems, research funding, food safety requirements, and seafood traceability expectations. BRICS countries represent large production, consumption, and biotechnology capacity, creating demand for scalable testing infrastructure and locally adaptable diagnostic platforms. GCC markets are investing in food security, controlled aquaculture, and aquatic health programs suited to arid environments, while NATO economies contribute advanced biotechnology, surveillance systems, risk analytics, and biosecurity research relevant to aquatic animal health and shrimp pathogen detection.

Key Country Insights Across Major Shrimp Diagnostics Markets

The United States and Canada are important for advanced diagnostics, reference laboratory capabilities, import oversight, seafood safety systems, and aquaculture health research, while Mexico and Brazil support regional diagnostic demand through shrimp farming, hatchery screening, and disease surveillance. The United Kingdom, Germany, France, Italy, and Spain influence European testing demand through seafood import requirements, veterinary diagnostics, biotechnology development, laboratory standards, and consumer expectations for traceable aquatic products.

China and India are among the most important country markets due to large shrimp aquaculture footprints, hatchery networks, recurring disease-management needs, and increasing use of molecular testing for pathogens such as WSSV, AHPND, EHP, and IHHNV. Japan and South Korea contribute high-value seafood demand, diagnostic technology adoption, and stringent quality expectations, while Australia applies strong biosecurity frameworks to protect domestic aquatic resources and manage aquatic animal disease risks. Russia remains relevant through seafood trade, cold-chain logistics, veterinary oversight, and demand for documented product safety across import and distribution channels.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize validated molecular diagnostics, standardized sampling, and routine screening across broodstock, hatcheries, nurseries, grow-out ponds, and processing interfaces. Integrating WSSV, AHPND, EHP, IHHNV, TSV, and IMNV panels into preventive health programs can reduce uncertainty, improve harvest planning, and support biosecurity decisions before mortality events escalate.

Organizations should also build data partnerships among farms, laboratories, feed suppliers, insurers, certification bodies, and buyers. Investments in AI-ready data architecture, technician training, quality assurance, rapid reporting, and interoperable laboratory information systems will convert diagnostic results into operational decisions and strengthen confidence across export-oriented seafood supply chains.

Research Methodology

The research methodology should combine secondary and primary intelligence from authoritative sources, including FAO aquaculture data, World Organisation for Animal Health aquatic animal health guidance, national veterinary authorities, peer-reviewed journals, diagnostic assay documentation, trade statistics, regulatory publications, and expert interviews with aquatic health specialists, laboratory professionals, producers, and supply-chain stakeholders.

Market assessment should triangulate disease prevalence indicators, aquaculture production patterns, diagnostic technology adoption, regulatory requirements, laboratory capacity, and buyer traceability expectations. A robust methodology also evaluates assay performance characteristics such as sensitivity, specificity, validation status, repeatability, throughput, turnaround time, cost per test, biosafety requirements, sample matrix compatibility, and field usability.

Conclusion

Shrimp disease diagnostics is transitioning from a laboratory service into a core aquaculture management capability. As disease pressure, climate variability, export scrutiny, antimicrobial stewardship, and production intensification increase, reliable pathogen detection will remain central to farm profitability, aquatic biosecurity, and seafood supply resilience.

The strongest opportunities will emerge where validated testing, AI-enabled risk analytics, regional biosecurity, and interoperable reporting converge. Organizations that treat diagnostics as a continuous intelligence system rather than an occasional outbreak tool will be best positioned to protect shrimp health, maintain market access, and support long-term aquaculture sustainability.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Shrimp Disease Diagnostics Market, by Technology

• 7.1. Enzyme Linked Immunosorbent Assay
• 7.2. Loop Mediated Isothermal Amplification
• 7.3. Next Generation Sequencing
• 7.4. Polymerase Chain Reaction
  • 7.4.1. Multiplex PCR
  • 7.4.2. Quantitative PCR
  • 7.4.3. Reverse Transcription PCR

8. Shrimp Disease Diagnostics Market, by Diagnostic Method

• 8.1. Histopathological Diagnostics
• 8.2. Immunological Diagnostics
  • 8.2.1. Enzyme Linked Immunosorbent Assay
  • 8.2.2. Lateral Flow Immunoassay
  • 8.2.3. Western Blot
• 8.3. Microbiological Diagnostics
• 8.4. Molecular Diagnostics

9. Shrimp Disease Diagnostics Market, by Disease Type

• 9.1. Bacterial Diseases
• 9.2. Fungal Diseases
• 9.3. Parasitic Diseases
• 9.4. Viral Diseases

10. Shrimp Disease Diagnostics Market, by Application

• 10.1. Monitoring
• 10.2. Outbreak Investigation
• 10.3. Research
• 10.4. Screening

11. Shrimp Disease Diagnostics Market, by End User

• 11.1. Academic Institutions
• 11.2. Aquaculture Farms
• 11.3. Diagnostic Laboratories
• 11.4. Research Institutes

12. Shrimp Disease Diagnostics Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Shrimp Disease Diagnostics Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Shrimp Disease Diagnostics Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. 3 Little Fish Sdn Bhd
• 16.2. Amazing Biotech
• 16.3. Aquaintech Inc.
• 16.4. Arachem (M) Sdn Bhd
• 16.5. Bioneer Corporation
• 16.6. Blue Aqua International Pte. Ltd.
• 16.7. CD Genomics
• 16.8. China Guangzhou BioKey Healthy Technology Co. Ltd
• 16.9. DSM Austria GmbH
• 16.10. Forte Biotech
• 16.11. GeneReach Biotechnology Corporation
• 16.12. Genics Pty. Ltd.
• 16.13. Illumina, Inc.
• 16.14. Innocreate Bioscience Co., Ltd.
• 16.15. Lab-Ind Resource Sdn. Bhd.
• 16.16. Laboratory Corporation of America Holdings
• 16.17. Mahesh Aqua Holdings (Pvt) Ltd.
• 16.18. Mylab Discovery Solutions Pvt. Ltd.
• 16.19. PT Riset Nusantara Genetika (Nusantics)
• 16.20. Randox Laboratories Ltd.
• 16.21. Reagen LLC
• 16.22. Ring Biotechnology Co Ltd.
• 16.23. Speedy Assay Sdn. Bhd.
• 16.24. SUREBIO
• 16.25. Thermo Fisher Scientific Inc.